- Home
- WLY vs GLPG Comparison
WLY vs GLPG Comparison
Compare WLY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLY
- GLPG
- Stock Information
- Founded
- WLY 1807
- GLPG 1999
- Country
- WLY United States
- GLPG Belgium
- Employees
- WLY N/A
- GLPG N/A
- Industry
- WLY Books
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- WLY Consumer Discretionary
- GLPG Health Care
- Exchange
- WLY Nasdaq
- GLPG Nasdaq
- Market Cap
- WLY 2.2B
- GLPG 2.1B
- IPO Year
- WLY N/A
- GLPG 2005
- Fundamental
- Price
- WLY $36.86
- GLPG $34.50
- Analyst Decision
- WLY
- GLPG Sell
- Analyst Count
- WLY 0
- GLPG 3
- Target Price
- WLY N/A
- GLPG $26.00
- AVG Volume (30 Days)
- WLY 333.0K
- GLPG 203.5K
- Earning Date
- WLY 09-04-2025
- GLPG 10-29-2025
- Dividend Yield
- WLY 3.86%
- GLPG N/A
- EPS Growth
- WLY N/A
- GLPG N/A
- EPS
- WLY 1.78
- GLPG N/A
- Revenue
- WLY $1,670,600,000.00
- GLPG $323,674,692.00
- Revenue This Year
- WLY $1.45
- GLPG $1.77
- Revenue Next Year
- WLY $2.70
- GLPG $0.44
- P/E Ratio
- WLY $20.66
- GLPG N/A
- Revenue Growth
- WLY N/A
- GLPG 5.43
- 52 Week Low
- WLY $36.10
- GLPG $22.36
- 52 Week High
- WLY $53.96
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- WLY 37.86
- GLPG 56.01
- Support Level
- WLY $37.93
- GLPG $34.62
- Resistance Level
- WLY $40.90
- GLPG $37.78
- Average True Range (ATR)
- WLY 0.81
- GLPG 0.77
- MACD
- WLY -0.26
- GLPG 0.11
- Stochastic Oscillator
- WLY 8.82
- GLPG 47.87
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.